GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism

Schizophrenia Research

Volumn 167, Issue 1-3, 2015, Pages 42-56

  Fatemi, S Hossein ^a   Folsom, Timothy D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bipolar disorder; Cerebellum; FMRP; GABA; MGluR5; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6; 4 AMINOBUTYRIC ACID A RECEPTOR BETA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 AMINOBUTYRIC ACID RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; METABOTROPIC RECEPTOR 5;

AUTISM; BINDING AFFINITY; BINDING SITE; CEREBELLUM; HUMAN; MOLECULAR PATHOLOGY; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AUTISTIC DISORDER; CEREBELLUM; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; MICE; MOOD DISORDERS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, GABA; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84942162910     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.010     Document Type: Review

References (184)

1. Adusei D.C., Pacey L.K., Chen D., Hampson D.R. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 2010, 59(3):167-171.
2. A receptor subunit gene in human prefrontal cortex: comparison of schizophrenics and controls. Cereb. Cortex 1995, 5(6):550-560.
3. Alakuijala A., Palgi M., Wegelius K., Schmidt M., Enz R., Paulin L., Saarma M., Pasternack M. GABA receptor rho subunit expression in the developing rat brain. Brain Res. Dev. Brain Res. 2005, 154(1):15-23.
4. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27(7):370-377.
5. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci. 2005, 6(7):565-575.
6. A receptor epsilon subunit has a number of unique properties. J. Neurophysiol. 2009, 102(4):2312-2325.
7. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 1992, 12(3):924-929.
8. A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996, 75(4):1021-1031.
9. A receptor binding in the hippocampal formation of schizophrenic brain. Synapse 1996, 22(4):338-349.
10. Benes F.M., Wickramasinghe R., Vincent S.L., Khan Y., Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res. 1997, 755(1):121-129.
11. Beneyto M., Abbott A., Hashimoto T., Lewis D.A. Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb. Cortex 2011, 21(5):999-1011.
12. Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., Hagerman R. A pilot open label, single dose of fenobam in adults with Fragile X syndrome. J. Med. Genet. 2009, 46(4):266-271.
13. Bigelow L.B., Nasrallah H., Carman J., Gillin J.C., Wyatt R.J. Baclofen treatment in chronic schizophrenia: a clinical trial. Am. J. Psychiatry 1977, 13(3):318-320.
14. Blatt G.J., Fatemi S.H. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat. Rec. (Hoboken) 2011, 294(10):1642-1652.
15. Blatt G.J., Fitzgerald C.M., Guptill J.T., Booker A.B., Kemper T.L., Bauman M.L. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J. Autism Dev. Disord. 2001, 31(6):537-544.
16. Bonnert T.P., McKernan R.M., Farrar S., le Bourdellès B., Heavens R.P., Smith D.W., Hewson L., Rigby M.R., Sirinathsinghji D.J., Brown N., Wafford K.A., Whiting P.J. Theta, a novel gamma-aminobutyric acid type A receptor subunit. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(17):9891-9896.
17. Boue-Grabot E., Roudbaraki M., Bascles L., Tramu G., Bloch B., Garret M. Expression of GABA receptor rho subunits in rat brain. J. Neurochem. 1998, 70(3):899-907.
18. B receptors structure and function. GABA in the Nervous System: The View at Fifty Years 2000, 233-244. Lippincott, Williams and Wilkins, Philadelphia, PA. D.L. Martin, R.W. Olsen (Eds.).
19. A receptors by protein phosphorylation. GABA in the Nervous System: The View at Fifty Years 2000, 191-206. Lippincott, Williams and Wilkins, Philadelphia, PA. D.L. Martin, R.W. Olsen (Eds.).
20. Braudeau J., Delatour B., Duchon A., Pereira P.L., Dauphinot L., de Chaumont F., Olivo-Marin J.C., Dodd R.H., Hérault Y., Potier M.C. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 2011, 25(8):1030-1042.
21. Brown V., Jin P., Ceman S., Darnell J.C., O'Donnell W.T., Tenenbaum S.A., Jin X., Feng Y., Wilkinson K.D., Keene J.D., Darnell R.B., Warren S.T. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107(4):477-487.
22. Brown E.S., Park J., Marx C.E., Hynan L.S., Gardner C., Davila D., Nakamura A., Sunderajan P., Lo A., Holmes T. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar disorder. Neuropsychopharmacology 2014, 39(12):2867-2873.
23. Buckle V.J., Fujita N., Bateson A.N., Darlison M.G., Barnard E.A. Localization of human GABA-A receptor subunit genes to chromosomes 4 and 5. Cytogenet. Cell Genet. 1989, 51:972.
24. Bullock W.M., Cardon K., Bustillo J., Roberts R.C., Perrone-Bizzozero N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am. J. Psychiatry 2008, 165(12):1594-1603.
25. Burman R.W., Yates P.A., Green L.D., Jacky P.B., Turker M.S., Popovich B.W. Hypomethylation of an expanded FMR1 allele is not associated with a global DNA methylation. Am. J. Hum. Genet. 1999, 65(5):1375-1386.
26. Carty N.C., Xu J., Kurup P., Brouillette J., Goebel-Goody S.M., Austin D.R., Yuan P., Chen G., Correa P.R., Haroutunian V., Pittenger C., Lombroso P.J. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Tranl. Psychiatry 2012, 2:e137.
27. Catania M.V., D'Antoni S., Bonaccorso C.M., Aronica E., Bear M.F., Nicoletti F. Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders?. Mol. Neurobiol. 2007, 35(3):298-307.
28. A receptors and their associated proteins: implications in the etiology of schizophrenia and related disorders. Neuropharmacology 2009, 57(5-6):481-495.
29. Chebib M., Johnston G.A. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J. Med. Chem. 2000, 43(8):1427-1474.
30. Chen L., Yun S.W., Seto J., Liu W., Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 2003, 120(4):1005-1017.
31. Chuang S.C., Zhao W., Bauchwitz R., Yan Q., Bianchi R., Wong R.K. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 2005, 25(35):8048-8055.
32. Coghlan S., Horder J., Inkster B., Mendez M.A., Murphy D.G., Nutt D.J. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci. Biobehav. Rev. 2012, 36(9):2044-2055.
33. Colak D., Zaninovic N., Cohen M.S., Rosenwaks Z., Yang W.Y., Gerhardt J., Disney M.D., Jaffrey S.R. Promoter-bound trinucleotide repeat RNA drives epigenetic silencing in fragile X syndrome. Science 2014, 343(6174):1002-1005.
34. Copani A., Romano C., Di Giorgi Gerevini V., Nicosia A., Casabona G., Storto M., Mutel V., Nicoletti F. Reducing conditions differentially affect the functional and structural properties of group-I and -II metabotropicglutamate receptors. Brain Res. 2000, 867(1-2):165-172.
35. Corti C., Xuereb J.H., Crepaldi L., Corsi M., Michielin F., Ferraguti F. Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 2011, 128(1-3):7-14.
36. A\-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat. Neurosci. 1999, 2(9):833-839.
37. Curia G., Papouin T., Seguela P., Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb. Cortex 2009, 19(7):1515-1520.
38. A receptor in fragile X syndrome. Brain Res. 2006, 1121(1):238-245.
39. Darnell J.C., Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 2013, 16(11):1530-1536.
40. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., Licatalosi D.D., Richter J.D., Darnell R.B. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146(2):247-261.
41. de Vrij F.M., Levenga J., van der Linde H.C., Koekkoek S.K., De Zeeuw C.I., Nelson D.L., Oostra B.A., Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 2008, 31(1):127-132.
42. A receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J. Neurosci. 1998, 18(20):8505-8514.
43. Delorey T.M., Sahbaie P., Hashemi E., Homanics G.E., Clark J.D. Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. Behav. Brain Res. 2008, 187(2):207-220.
44. Deng P.Y., Sojka D., Klyachko V.A. Abnormal presynaptic short-term plasticity and information processing in a mouse model of fragile X syndrome. J. Neurosci. 2011, 31(30):10971-10982.
45. Deng P.Y., Rotman Z., Blundon J.A., Cho Y., Cui J., Cavalli V., Zakharenko S.S., Klyachko V.A. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 2013, 77(4):696-711.
46. Deschwanden A., Karolewicz B., Feyissa A.M., Treyer V., Ametamey S.M., Johayem A., Burger C., Auberson Y.P., Sovago J., Stockmeyer C.A., Buck A., Hasler G. Reduced metabotropic glutamate receptor 5 density in major depression determined by ((11)C)ABP688 PET and postmortem study. Am. J. Psychiatry 2011, 168(7):724-734.
47. Devys D., Lutz Y., Rouyer N., Bellocq J.P., Mandel J.L. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat. Genet. 1993, 4(4):335-340.
48. Dölen G., Bear M.F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol. 2008, 586(6):1503-1508.
49. Duncan C.E., Webster M.J., Rothmond D.A., Bahn S., Elashoff M., Shannon Weickert C. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J. Psychiatr. Res. 2010, 44(10):673-681.
50. Earnheart J.C., Schweizer C., Crestani F., Iwasato T., Itohara S., Mohler H., Lüscher B. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 2007, 27(14):3845-3854.
51. A receptor expression in the seizure-prone fragile X mouse. Neurosci. Lett. 2005, 377(3):141-146.
52. A receptor delta-subunit gene (GABRD) to chromosome band 1p36.3 distal to marker NIB1364 by radiation hybrid mapping. Cytogenet. Cell Genet. 2000, 89(3-4):281-282.
53. A Receptors 2014, 1-14. Springer Science+Business Media, New York. A.C. Errington, G. Di Giovanni, V. Crunelli (Eds.).
54. Farrar S.J., Whiting P.J., Bonnert T.P., McKernan R.M. Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer. J. Biol. Chem. 1999, 274(15):10100-10104.
55. Fatemi S.H., Folsom T.D. Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol. Autism 2011, 2:6-16.
56. Fatemi S.H., Folsom T.D. Existence of monomer and dimer forms of mGluR5, under reducing conditions in studies of postmortem brain in various psychiatric disorders. Schizophr. Res. 2014, 158(1-3):270-271.
57. Fatemi S.H., Reutiman T.J., Folsom T.D., Thuras P.D. GABA(A) receptor downregulation in brains of subjects with autism. J. Autism Dev. Disord. 2009, 39(2):223-230.
58. Fatemi S.H., Folsom T.D., Reutiman T.J., Thuras P.D. Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum 2009, 8(1):64-69.
59. Fatemi S.H., Reutiman T.J., Folsom T.D., Rooney R.J., Patel D.H., Thuras P.D. mRNA and protein levels for GABAAalpha4, alpha5, beta1, and GABABR1 receptors are altered in brains of subjects with autism. J. Autism Dev. Disord. 2010, 40(6):743-750.
60. Fatemi S.H., Kneeland R.E., Liesch S.B., Folsom T.D. Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr. Res. 2010, 124(1-3):246-247.
61. A receptor beta 3 in adults with autism. Anat. Rec. 2011, 294(10):1635-1645.
62. Fatemi S.H., Folsom T.D., Thuras P.D. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr. Res. 2011, 128(1-3):37-43.
63. A receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl. Psychiatry 2013, 3:e271.
64. A α2-, β1- and ε-receptors are altered signi'ficantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder. Transl. Psychiatry 2013, 3:e303.
65. Fatemi S.H., Folsom T.D., Kneeland R.E., Yousefi M.K., Liesch S.B., Thuras P.D. Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex. Mol. Autism 2013, 4:21.
66. A receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J. Autism Dev. Disord. 2014, 44(8):1833-1845.
67. B receptors ameliorates sensorimotor gating in rodent models. CNS Neurosci. Ther. 2014, 20(7):679-684.
68. Frederiksen P.K. Letter: Baclofen in the treatment of schizophrenia. Lancet 1975, 1(7908):702.
69. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., Georgieva L., Rees E., Palta P., Ruderfer D.M., Carrera N., Humphreys I., Johnson J.S., Roussos P., Barker D.D., Banks E., Milanova V., Grant S.G., Hannon E., Rose S.A., Chambert K., Mahajan M., Scolnick E.M., Moran J.L., Kirov G., Palotie A., McCarroll S.A., Holmans P., Sklar P., Owen M.J., Purcell S.M., O'Donovan M.C. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506(7487):179-184.
70. B-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl. Psychiatry 2012, 2:e142.
71. A receptor subunit delta in the fragile X knockout mouse model. Neurobiol. Dis. 2006, 21(2):346-357.
72. A receptors are involved in the development of the latent inhibition effect. Neurobiol. Learn. Mem. 2008, 89(2):87-94.
73. Glausier J.R., Lewis D.A. Selective pyramidal cell reduction of GABA(A) receptor α1 subunit messenger RNA expression in schizophrenia. Neuropsychopharmacology 2011, 36(10):2103-2110.
74. Goebel-Goody S.M., Baum M., Paspalas C.D., Fernandez S.M., Carty N.C., Kurup P., Lombroso P.J. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 2012, 64(1):65-87.
75. Goei V.L., Choi J., Ahn J., Bowlus C.L., Raha-Chowdhury R., Gruen J.R. Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization. Biol. Psychiatry 1998, 44(8):659-666.
76. Gonzalez-Burgos G., Fish K.N., Lewis D.A. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011, 2011:723184.
77. Goudet C., Kniazeff J., Hlavackova V., Malhaire F., Maurel D., Acher F., Blahos J., Prézeau L., Pin J.-P. Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 2005, 280(26):24380-24385.
78. Greger V., Knoll J.H., Woolf E., Glatt K., Tyndale R.F., DeLorey T.M., Olsen R.W., Tobin A.J., Sikela J.M., Nakatsu Y. The gamma-aminobutyric acid receptor gamma 3 subunit gene (GABRG3) is tightly linked to the alpha 5 subunit gene (GABRA5) on human chromosome 15q11-q13 and is transcribed in the same orientation. Genomics 1995, 26(2):258-264.
79. Gulmann N.C., Bahr B., Andersen B., Eliassen H.M. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr. Scand. 1976, 54(4):287-293.
80. Gulyás B., Sovago J., Gomez-Mancilla B., Jia Z., Szigeti C., Gulya K., Schumacher M., Maguire R.P., Gasparini F., Halldin C. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain. Brain Struct. Funct. 2014, (in press).
81. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57(3):123-131.
82. Gürkan C.K., Hagerman R.J. Targeted treatments in autism and fragile X syndrome. Res. Autism Spectr. Disord. 2012, 6(4):1311-1320.
83. Hagerman R.J., Des-Portes V., Gasparini F., Jacquemont S., Gomez-Mancilla B. Translating molecular advances in fragile X syndrome into therapy: a review. J. Clin. Psychiatry 2014, 75(4):e294-e307.
84. Han Y., Qin J., Bu D.F., Chang X.Z., Yang Z.X. Successive alterations of hippocampal gamma-aminobutyric acid B receptor subunits in a rat model of febrile seizure. Life Sci. 2006, 78(25):2944-2952.
85. Harvey V.L., Duguid I.C., Krasel C., Stephens G.J. Evidence that GABA rho subunits contribute to functional GABA receptors in mouse cerebellar Purkinje cells. J. Physiol. 2006, 577(Pt 1):127-139.
86. Hashimoto T., Arion D., Unger T., Maldonado-Avilés J.G., Morris H.M., Volk D.W., Mirnics K., Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13(2):147-161.
87. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(5):367-377.
88. A receptor subunit in tissues of the reproductive system. J. Biol. Chem. 1997, 272(24):15346-15350.
89. B receptors with arbaclofen. Sci. Transl. Med. 2012, 4(152):152ra128.
90. Herman E.J., Bubser M., Conn P.J., Jones C.K. Metabotropic glutamate receptors for new treatments in schizophrenia. Hanb. Exp. Pharmacol. 2012, 2012(213):297-365.
91. Heulens I., D'Hulst C., Braat S., Rooms L., Kooy R.F. Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome. ScientificWorldJournal 2010, 10:2198-2206.
92. Heulens I., D'Hulst C., Van Dam D., De Deyn P.P., Kooy R.F. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res. 2012, 229(1):244-249.
93. A receptor subunit genes: localization of the alpha 6-subunit gene (GABRA6) to distal chromosome 5q by linkage analysis. Genomics 1994, 20(2):285-288.
94. A receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum. Mol. Genet. 2007, 16(6):691-703.
95. Hong A., Zhang A., Ke Y., El Idrissi A., Shen C.H. Downregulation of GABA(A) β subunits is transcriptionally controlled by Fmr1p. J. Mol. Neurosci. 2012, 46(2):272-275.
96. Hou L., Antion M.D., Hu D., Spencer C.M., Paylor R., Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006, 51(4):441-454.
97. Iossifov I., Ronemus M., Levy D., Wang Z., Hakker I., Rosenbaum J., Yamrom B., Lee Y.H., Narzisi G., Leotta A., Kendall J., Grabowska E., Ma B., Marks S., Rodgers L., Stepansky A., Troge J., Andrews P., Bekritsky M., Pradhan K., Ghiban E., Kramer M., Parla J., Demeter R., Fulton L.L., Fulton R.S., Magrini V.J., Ye K., Darnell J.C., Darnell R.B., Mardis E.R., Wilson R.K., Schatz M.C., McCombie W.R., Wigler M. De novo gene disruptions in children on the autistic spectrum. Neuron 2012, 74(2):285-299.
98. Irwin S.A., Idupulapati M., Gilbert M.E., Harris J.B., Chakravarti A.B., Rogers E.J., Crisostomo R.A., Larsen B.P., Mehta A., Alcantara C.J., Patel B., Swain R.A., Weiler I.J., Oostra B.A., Greenough W.T. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile X-knockout mice. Am. J. Med. Genet. 2002, 111(2):140-146.
99. Kasparov S., Davies K.A., Patel U.A., Boscan P., Garret M., Paton J.F. GABA(A) receptor epsilon-subunit may confer benzodiazepine insensitivity to the caudal aspect of the nucleus tractus solitarii of the rat. J. Physiol. 2001, 536(Pt 3):785-796.
100. Kelemen O., Kovács T., Kéri S. Contrast, motion, perceptual integration, and neurocognition in schizophrenia: the role of fragile X-related mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:92-97.
101. Kirkness E.F., Kusiak J.W., Fleming J.T., Menninger J., Gocayne J.D., Ward D.C., Venter J.C. Isolation, characterization, and localization of human genomic DNA encoding the beta-1 subunit of the GABA-A receptor (GABRB1). Genomics 1991, 10(4):985-995.
102. Knoll J.H.M., Sinnett D., Wagstaff J., Glatt K., Wilcox A.S., Whiting P., Wingrove P., Sikela J., Lalande M. FISH ordering of DNA markers within the Angelman/Prader-Willi chromosomal regions: mapping of a second GABA-A receptor subunit gene, GABRA5. Am. J. Hum. Genet. 1992, 51:A9. (Abstract), (Suppl.).
103. Korpi E.R., Gründer G., Lüddens H. Drug interactions at GABA(A) receptors. Prog. Neurobiol. 2002, 67(2):113-159.
104. Kovács T., Keleman O., Kéri S. Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. Psychiatry Res. 2013, 210(3):81-89.
105. Kreinin A., Bawakny H., Ritsner M.S. Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia. Clin. Schizophr. Relat. Psychoses 2014, 4:1-31.
106. Kuriyama K., Hirouchi M., Kimura H. Neurochemical and molecular pharmacological aspects of the GABA(B) receptor. Neurochem. Res. 2000, 25(9-10):1233-1239.
107. A receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J. Neurosci. 1992, 12(11):1063-1076.
108. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71(2):138-149.
109. Li S.P., Park M.S., Yoon H., Rhee K.H., Bahk J.Y., Lee J.H., Park J.S., Kim M.O. Differential distribution of GABA(B1) and GABA(B2) receptor mRNAs in the rat brain. Mol. Cells 2003, 16(1):40-47.
110. Lohith T.G., Osterweil E.K., Fujita M., Jenko K.J., Bear M.F., Innis R.B. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome. Mol. Autism 2013, 4(1):15.
111. Luo L., Hensch T.K., Ackerman L., Barbel S., Jan L.Y., Jan Y.N. Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines. Nature 1996, 379(6568):837-840.
112. Luscher B., Shen Q., Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 2011, 16(4):383-406.
113. Ma D.Q., Whitehead P.L., Menold M.M., Martin E.R., Ashley-Koch A.E., Mei H., Ritchie M.D., Delong G.R., Abramson R.K., Wright H.H., Cuccaro M.L., Hussman J.P., Gilbert J.R., Pericak-Vance M.A. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am. J. Hum. Genet. 2005, 77(3):377-388.
114. Maier K., Merkler D., Gerber J., Taheri N., Kuhnert A.V., Williams S.K., Neusch C., Bähr M., Diem R. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis. 2007, 25(3):514-525.
115. Maldonado-Avilés J.G., Curley A.A., Hashimoto T., Morrow A.L., Ramsey A.J., O'Donnell P., Volk D.W., Lewis D.A. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2009, 166(4):450-459.
116. A Receptors 2014, 271-284. Springer Science+Business Media, New York. A.C. Errington, G. Di Giovanni, V. Crunelli (Eds.).
117. Martin S.C., Russek S.J., Farb D.H. Molecular identification of the human GABA(B)R1: cell surface expression and coupling to adenylyl cyclase in the absence of GABA(B)R2. Mol Cell Neurosci 1999, 13(3):180-191.
118. Martin B.S., Corbin J.G., Huntsman M.M. Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala. J. Neurophysiol. 2014, 112(4):890-902.
119. A α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 2013, 33(9):3953-3966.
120. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003, 28(1):1-13.
121. Marx C.E., Shampine L.J., Khisti R.T., Trost W.T., Bradford D.W., Grobin A.C., Massing M.W., Madison R.D., Butterfield M.I., Lieberman J.A., Morrow A.L. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol. Biochem. Behav. 2006, 84(4):609-617.
122. Marx C.E., Shampine L.J., Duncan G.E., VanDoren M.J., Grobin A.C., Massing M.W., Madison R.D., Bradford D.W., Butterfield M.I., Lieberman J.A., Morrow A.L. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?. Pharmacol. Biochem. Behav. 2006, 84(4):598-608.
123. Marx C.E., Keefe R.S., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L., Shampine L.J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34(8):1885-1903.
124. Matosin N., Frank E., Deng C., Huang X.-F., Newell K.A. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr. Res. 2013, 146(1-3):170-176.
125. Matosin N., Fernandez-Enright F., Frank E., Deng C., Wong J., Huang X.F., Newell K.A. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J. Psychiatry Neurosci. 2014, 39(4):130242.
126. McCauley J.L., Olson L.M., Delahanty R., Amin T., Nurmi E.L., Organ E.L., Jacobs M.M., Folstein S.E., Haines J.L., Sutcliffe J.S. A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 131(1):51-59.
127. McLean P.J., Farb D.H., Russek S.J. Mapping of the alpha(4) subunit gene (GABRA4) to human chromosome 4 defines an alpha(2)-alpha(4)-beta(1)-gamma(1) gene cluster: further evidence that modern GABA(A) receptor gene clusters are derived from an ancestral cluster. Genomics 1995, 26(3):580-586.
128. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol. 2008, 31(5):287-292.
129. Miyashiro K.Y., Beckel-Mitchener A., Purk T.P., Becker K.G., Barret T., Liu L., Carbonetto S., Weiler I.J., Greenough W.T., Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003, 37(3):417-431.
130. Mizoguchi H., Yamada K. Pharmacologic treatment with GABA(B) receptor agonist of methamphetamine-induced cognitive impairment in mice. Curr. Neuropharmacol. 2011, 9(1):109-112.
131. Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012, 62(1):42-53.
132. Moragues N., Ciofi P., Tramu G., Garret M. Localisation of GABA(A) receptor epsilon-subunit in cholinergic and aminergic neurones and evidence for co-distribution with the theta-subunit in rat brain. Neuroscience 2002, 111(3):657-669.
133. Nakayama A.Y., Harms M.B., Luo L. Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J. Neurosci. 2000, 20(14):5329-5338.
134. Nalavadi V.C., Muddashetty R.S., Gross C., Bassell G.J. Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation. J. Neurosci. 2012, 32(8):2582-2587.
135. Oblak A.L., Gibbs T.T., Blatt G.J. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J. Neurochem. 2010, 114(5):1414-1423.
136. Oblak A.L., Gibbs T.T., Blatt G.J. Reduced GABA(A) receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011, 1380:218-228.
137. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res. Mol. Brain Res. 2000, 85(1-2):24-31.
138. Oka A., Takashima S. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol. 1999, 97(3):275-278.
139. Olmos-Serrano J.L., Paluszkiewicz S.M., Martin B.S., Kaufmann W.E., Corbin J.G., Huntsman M.M. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 2010, 30(29):9929-9938.
140. Ota V.K., Noto C., Gadelha A., Santoro M.L., Ortiz B.B., Andrade E.H., Tasso B.C., Spindola L.M., Silva P.N., Abílio V.C., Smith M.D., Sato J.R., Brietzke E., Cordeiro Q., Bressan R.A., Belangero S.I. Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis. J. Psychiatr. Res. 2014, S0022-3956(14):150-152.
141. Paribello C., Tao L., Folino A., Berry-Kravis E., Tranfaglia M., Ethell I.M., Ethell D.W. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010, 10:91.
142. Pi R., Li W., Lee N.T., Chan H.H., Pu Y., Chan L.N., Sucher N.J., Chang D.C., Li M., Han Y. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J. Neurochem. 2004, 91(5):1219-1230.
143. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., Nelson D.L. Absence of expression of FMR-1 gene in fragile X syndrome. Cell 1991, 66(4):817-822.
144. Pinna G., Costa E., Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006, 186(3):362-372.
145. Pinna G., Costa E., Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr. Opin. Pharmacol. 2009, 9(1):24-30.
146. Pirker S., Schwarzer C., Wieselthaler A., Sieghart W., Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000, 101(4):815-850.
147. Pirker S., Schwarzer C., Czech T., Baumgartner C., Pockberger H., Maier H., Hauer B., Sieghart W., Furtinger S., Sperk G. Increased expression of GABA(A) receptor beta-subunits in the hippocampus of patients with temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 2003, 62(8):820-834.
148. Pretto D.I., Kumar M., Cao Z., Cunningham C.L., Durbin-Johnson B., Qi L., Berman R., Noctor S.C., Hagerman R.J., Pessah I.N., Tassone F. Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome. Neurobiol. Aging 2014, 35(5):1189-1197.
149. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 2006, 26(27):7212-7221.
150. Princivalle A.P., Richards D.A., Duncan J.S., Spreafico R., Bowery N.G. Modification of GABA(B1) and GABA(B2) receptor subunits in the somatosensory cerebral cortex and thalamus of rats with absence seizures (GAERS). Epilepsy Res. 2003, 55(1-2):39-51.
151. Purcell S.M., Moran J.L., Fromer M., Ruderfer D., Solovieff N., Roussos P., O'Dushlaine C., Chambert K., Bergen S.E., Kähler A., Duncan L., Stahl E., Genovese G., Fernández E., Collins M.O., Komiyama N.H., Choudhary J.S., Magnusson P.K., Banks E., Shakir K., Garimella K., Fennell T., DePristo M., Grant S.G., Haggarty S.J., Gabriel S., Scolnick E.M., Lander E.S., Hultman C.M., Sullivan P.F., McCarroll S.A., Sklar P. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506(7487):185-190.
152. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., Meador-Woodruff J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry 2000, 47(1):22-28.
153. Ritsner M.S., Gibel A., Shleifer T., Boguslavsky I., Zayed A., Maayan R., Weizman A., Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 2010, 71(10):1351-1362.
154. Ritsner M.S., Bawakny H., Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin. Neurosci. 2014, 68(8):432-440.
155. Romano C., Miller J.K., Hyrc K., Dikranian S., Mennerick S., Takeuchi Y., Goldberg M.P., O'Malley K.L. Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGluR5 dimerization. Mol. Pharmacol. 2001, 59(1):46-53.
156. A receptor isoform. Genomics 1994, 23(3):528-533.
157. Rustan O.G., Folsom T.D., Yousefi M.K., Fatemi S.H. Phosphorylated fragile X mental retardation protein at serine 499, is reduced in cerebellar vermis and superior frontal cortex of subjects with autism: implications for fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling. Mol. Autism 2013, 4(1):41.
158. Samaco R.C., Hogart A., LaSalle J.M. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum. Mol. Genet. 2005, 14(4):483-492.
159. Sanchez-Pernaute R., Wang J.Q., Kuruppu D., Cao L., Tueckmantel W., Kozikowski A., Isacson O., Brownell A.L. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 2008, 42(1):248-251.
160. Schroer R.J., Phelan M.C., Michaelis R.C., Crawford E.C., Skinner S.A., Cuccaro M., Simensen R.J., Bishop J., Skinner C., Fender D., Stevenson R.E. Autism and maternally derived aberrations of chromosome 15q. Am. J. Med. Genet. 1998, 76(4):327-336.
161. Schüle C., Northdurfter C., Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog. Neurobiol. 2014, 113:79-87.
162. Schwarzer C., Berresheim U., Pirker S., Wieselthaler A., Fuchs K., Sieghart W., Sperk G. Distribution of the major gamma-aminobutyric acid(A) receptor subunits in the basal ganglia and associated limbic brain areas of the adult rat. J. Comp. Neurol. 2001, 433(4):526-549.
163. Schwendt M., McGinty J.F. Regulator of G-protein signaling 4 interacts with metabotropic glutamate receptor 5 in rat striatum: relevance to amphetamine behavioral sensitization. J. Pharmacol. Exp. Ther. 2007, 323(2):650-657.
164. A receptors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(24):14439-14444.
165. B receptors in a mouse model of temporal lobe epilepsy. Eur. J. Neurosci. 2003, 18(8):2213-2226.
166. Sur C., Wafford K.A., Reynolds D.S., Hadingham K.L., Bromidge F., Macaulay A., Collinson N., O'Meara G., Howell O., Newman R., Myers J., Atack J.R., Dawson G.R., McKernan R.M., Whiting P.J., Rosahl T.W. Loss of the major GABA(A) receptor subtype in the brain is not lethal to mice. J. Neurosci. 2001, 21(10):3409-3418.
167. Szumlinski K.K., Kalivas P.W., Worley P.F. Homer proteins: implications for neuropsychiatric disorders. Curr. Opin. Neurobiol. 2006, 16(3):251-257.
168. Thompson S.A., Bonnert T.P., Cagetti E., Whiting P.J., Wafford K.A. Overexpression of the GABA(A) receptor epsilon subunit results in insensitivity to anesthetics. Neuropharmacology 2002, 43(4):662-668.
169. Threadgill R., Bobb K., Ghosh A. Regulation of dendritic growth and remodeling by Rho, Rac, and Cdc42. Neuron 1997, 19(3):625-634.
170. Tsamis K.I., Mytilinaios D.G., Njau S.N., Baloyannis S.J. Glutamate receptors in human caudate nucleus in normal aging and Alzheimer's disease. Curr. Alzheimer Res. 2013, 10(5):469-475.
171. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurol. 2002, 1(6):352-358.
172. Turner P.R., O'Connor K., Tate W.P., Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 2003, 70(1):1-32.
173. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 2010, 167(10):1489-1498.
174. Vollenweider I., Smith K.S., Keist R., Rudolph U. Antidepressant-like properties of α-containing GABA(A) receptors. Behav. Brain Res. 2011, 217(1):77-80.
175. A Receptors 2014, 51-74. Springer Science+Business Media, New York. A.C. Errington, G. Di Giovanni, V. Crunelli (Eds.).
176. Wafford K.A., Ebert B. Gaboxadol-a new awakening in sleep. Curr. Opin. Pharmacol. 2006, 6(1):30-36.
177. Wang H., Westin L., Nong Y., Birnbaum S., Bendor J., Brismar H., Nestler E., Aperia A., Flajolet M., Greengard P. Norbin in an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science 2009, 326(5959):1554-1557.
178. Wang L.W., Berry-Kravis E., Hagerman R.J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010, 7(3):264-274.
179. Weiler I.J., Greenough W.T. Synaptic synthesis of the fragile X protein: possible involvement in synapse maturation and elimination. Am. J. Med. Genet. 1999, 83(4):248-252.
180. Whiting P.J., Bonnert T.P., McKernan R.M., Farrar S., le Bourdelles B., Heavens R.P., Smith D.W., Hewson L., Rigby M.R., Sirinathsinghji D.J.S., Thompson S.A., Wafford K.A. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann. N.Y. Acad. Sci. 1999, 868:645-653.
181. Wilcox A.S., Warrington J.A., Gardiner K., Berger R., Whiting P., Altherr M.R., Wasmuth J.J., Patterson D. Human chromosomal localization of genes encoding the gamma 1 and gamma 2 subunits of the gamma-aminobutyric acid receptor indicates that members of this gene family are often clustered in the genome. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(13):5857-5861.
182. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci. 1992, 12(3):1040-1062.
183. Wong P., Chang C.C., Marx C.E., Caron M.G., Wetsel W.C., Zhang X. Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. PLoS One 2012, 7(12):e51455.
184. A receptors to a dopamine hyperfunction. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(47):17154-17159.